OPTIMAL TRIGLYCERIDE LIMITS DURING FASTING AND FEEDING FOR PREDICTION OF ISCHAEMIC HEART DISEASE: THE CARDIOVASCULAR RISK STUDY (CVRS)
Keywords:
Triglycerides, Optimal cut-off point, Coronary heart disease, General population, Cohort studyAbstract
The optimal cut-off points for satiety and fasting were 145 mg/dl and 110 mg/dl, with C-statistics of 0.594 and 0.626, Youden index of 0.187 and 0.252, and Harrell's fit statistic of 0.590 and 0.630. The corresponding multivariate hazard ratios for ischemic heart disease were 1.43 (95% CI 1.09-1.88) and 1.69 (1.03-2.77), and the corresponding population fractions were 16.1% (95% CI 3.3-27.2%) and the optimal cut-off point was (24.3-3.6 points). The fasting and fasting triglyceride levels in the general population of Bukhara were 145 mg/dl and 110 mg/dl.
References
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, and Yeboah J: 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation, 2019; 139: e1082-e1143
Tada H, Takamura M, and Kawashiri MA: Triglycerides on the Rise J Atheroscler Thromb, 2021; 28: 1263-1265
Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, and Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153: 490-499
Yamagishi K, Iso H, Sairenchi T, Irie F, Takizawa N, Koba A, Tomizawa T, and Ota H: Diabetes mellitus modifies the association of serum triglycerides with ischemic cardiovascular disease mortality: The Ibaraki Prefectural Health Study (IPHS). J Atheroscler Thromb, 2021, online ahead of print. DOI: 10.5551/jat.63081
Higashiyama A, Wakabahashi I, Okamura T, Kokubo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okahama A, and Miyamoto Y: The risk of fasting triglycerides and its related indices for ischemic cardiovascular diseases in Japanese community dwellers: the Suita Study. J Atheroscler Thromb, 2021; 28: 1275-1288
Iso H, Imano H, Yamagishi K, Ohira T, Cui R, Noda H, Sato S, Kiyama M, Okada T, Hitsumoto S, Tanigawa T, Kitamura A, and CIRCS Investigators: Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2014; 237: 361-368
Nordestgaard BG: A Test in Context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol, 2017; 70: 1637-1646
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, and Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298: 309-316
Mora S, Rifai N, Buring JE, and Ridker PM: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation, 2008; 118: 993-1001
Langsted A, Freiberg JJ, and Nordestgaard BG: Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation, 2008; 118: 2047-2056
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, and Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152
Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, and Nordestgaard BG: Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med, 2011; 270: 65-75
Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, and Nordestgaard BG: Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol, 2013; 61: 427-436
Nordestgaard BG, Hilsted L, Stender S: Plasma lipids in non-fasting patients and signal values of laboratoryresults. Ugeskr Laeger, 2009; 171: 1093
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333
Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Downs JR, O’Malley PG. Ann Intern Med, 2015; 163: 291-297
NICE Guidance. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE. Updated 2016. Available at: https: //www.nice.org.uk/guidance/cg181
White KT, Moorthy MV, Akinkuolie AO, Demler O, Ridker PM, Cook NR, and Mora S: Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state. Clin Chem, 2015; 61: 1156-1163
